Key facts
- ReCode Therapeutics’s last known valuation is $700.0M (Sep 2023).
- It has raised $388.0M across 3 recorded rounds; the latest was Later Stage VC ($259.8M) in Oct 2021.
- Notable investors include Evolution VC Partners, OrbiMed, Osage University Partners, Blockchange Ventures, Pfizer Ventures — 24 tracked in total.
- ReCode Therapeutics has filed 5 Form Ds with the SEC since 2020, most recently Sep 2023 ($259.8M sold to 28 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 24 names
- ·Watchlist + deal alerts for ReCode Therapeutics
Funding rounds
3 roundsAbout ReCode Therapeutics
Developer of targeted delivery technology designed for patients with rare diseases. The company's platform utilizes lipid nanoparticles to precisely deliver corrective or disease-modifying genetic therapies to specific organs and tissues, potentially overcoming limitations of current gene therapy methods and offering new hope for patients with unmet medical needs, enabling healthcare firms with life-limiting respiratory diseases to avail themselves of medicines.
- Sector
- Healthcare
- HQ
- Menlo Park, CA, United States
- Founded
- 2015
- Employees
- 105
- Website
- recodetx.com/
- Ownership
- Privately Held (backing)
ReCode Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ReCode Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ReCode Therapeutics in its N-PORT filings yet. We sweep new filings monthly.